# Vision Response to Dopamine Replacement

> **NCT01663935** · PHASE2 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 20 (actual)

## Conditions studied

- Albinism
- Oculocutaneous Albinism

## Interventions

- **DRUG:** Levodopa/carbidopa

## Key facts

- **NCT ID:** NCT01663935
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-17
- **Primary completion:** 2018-04-12
- **Final completion:** 2018-04-12
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2019-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663935, "Vision Response to Dopamine Replacement". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01663935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*